ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Randomized Trial"

  • Abstract Number: 1348 • ACR Convergence 2020

    What Influence Do Clinical Domains Other Than Arthritis Have on Composite Clinical Outcomes in Psoriatic Arthritis?: Comparison of Treatment Effects in the SEAM-PsA Trial

    Philip Helliwell1, Philip Mease2, Arthur Kavanaugh3, Laura Coates4, Alexis Ogdie5, Atul Deodhar6, Vibeke Strand7, Ervant Maksabedian8, Gregory Kricorian9, Lyrica Liu9, David Collier10 and Dafna Gladman11, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 3UC San Diego Health System, San Diego, CA, 4University of Oxford, Oxford, United Kingdom, 5University of Pennsylvania, Philadelphia, PA, 6Oregon Health & Science University, Portland, OR, 7Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 8Amgen Inc., LOS ANGELES, CA, 9Amgen Inc., Thousand Oaks, CA, 10Amgen, Thousand Oaks, CA, 11Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Psoriatic arthritis is broadly characterized by clinical domains such as enthesitis, dactylitis, nail manifestations, and psoriasis.  How these clinical domains influence the response to…
  • Abstract Number: 2023 • ACR Convergence 2020

    Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 1-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension

    Atul Deodhar1, Désirée van der Heijde2, Joachim Sieper3, Filip Van den Bosch4, Walter Maksymowych5, Tae-Hwan Kim6, Mitsumasa Kishimoto7, Andrew Östör8, Bernard Combe9, Yunxia Sui10, Xin Wang10, Alvina D. Chu11 and In-Ho Song10, 1Oregon Health & Science University, Portland, OR, 2Leiden University Medical Center, Leiden, Netherlands, 3Charité Universitätsmedizin Berlin, Berlin, Germany, 4Ghent University Hospital, Ghent, Belgium, 5University of Alberta, Edmonton, AB, Canada, 6Hanyang University Hospital for Rheumatic Diseases, Seoul, Seoul-t'ukpyolsi, Republic of Korea, 7Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, 8Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, 9University of Montpellier, Montpellier, France, 10AbbVie Inc., North Chicago, IL, 11AbbVie, North Chicago, IL

    Background/Purpose: Upadacitinib (UPA), a Janus kinase (JAK) inhibitor, was efficacious and well tolerated vs placebo (PBO) during the first 14 weeks (wks) of the phase…
  • Abstract Number: 0886 • ACR Convergence 2020

    Achievement of Partial Remission and Inactive Disease in Upadacitinib-Treated Patients with Ankylosing Spondylitis

    Atul Deodhar1, Andrew Östör2, Anna Maniccia3, Fabiana Ganz4, Tianming Gao3, Alvina D. Chu5 and Denis Poddubnyy6, 1Oregon Health & Science University, Portland, OR, 2Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, 3AbbVie Inc., North Chicago, IL, 4AbbVie Inc., Baar, Switzerland, 5AbbVie, North Chicago, IL, 6Charité – Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: Assessment of SpondyloArthritis international Society (ASAS) response criteria and AS Disease Activity Score (ASDAS) are both commonly used, rigorous composite indices consisting of components…
  • Abstract Number: 1372 • ACR Convergence 2020

    Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis and Axial Involvement

    Atul Deodhar1, Roberto Ranza2, Fabiana Ganz3, Tianming Gao4, Jaclyn K Anderson4 and Andrew Östör5, 1Oregon Health & Science University, Portland, OR, 2Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlândia, Brazil, 3AbbVie Inc., Baar, Switzerland, 4AbbVie Inc., North Chicago, IL, 5Cabrini Medical Center, Monash University, Malvern, Victoria, Australia

    Background/Purpose: Upadacitinib (UPA) has demonstrated efficacy for the treatment of AS in patients (pts) who were NSAID inadequate responders (IR).1 Pts with psoriatic arthritis (PsA)…
  • Abstract Number: 2024 • ACR Convergence 2020

    Effects of Filgotinib on Spinal Lesions in Patients with Ankylosing Spondylitis: Magnetic Resonance Imaging Data from the Placebo-Controlled, Double‑Blind, Randomized TORTUGA Trial

    Walter Maksymowych1, Mikkel Østergaard2, Robert Landewé3, William Barchuk4, Ke Liu4, Chantal Tasset5, Leen Gilles5, Thijs Hendrikx6, Robin Besuyen6 and Xenofon Baraliakos7, 1University of Alberta, Edmonton, AB, Canada, 2Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 3Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, 4Gilead Sciences, Inc., Foster City, CA, 5Galapagos NV, Mechelen, Belgium, 6Galapagos BV, Leiden, Netherlands, 7Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany

    Background/Purpose: The oral, selective Janus kinase 1 inhibitor filgotinib (FIL) significantly improved Spondyloarthritis Research Consortium of Canada (SPARCC) MRI inflammation scores (bone marrow edema) in…
  • Abstract Number: 0896 • ACR Convergence 2020

    Impact of Upadacitinib on Reducing Pain in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials in Patients with Inadequate Response to Non-biologic or Biologic DMARDs

    Iain McInnes1, William Tillett2, Philip Mease3, Kurt de Vlam4, Louis Bessette5, Ralph Lippe6, Anna Maniccia7, Patrick Zueger7, Dai Feng7, Koji Kato8 and Andrew Östör9, 1Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, 3Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 4Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium, 5Laval University, Quebec, Canada, 6AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 7AbbVie Inc., North Chicago, IL, 8AbbVie Inc, North Chicago, IL, 9Cabrini Medical Center, Monash University, Malvern, Victoria, Australia

    Background/Purpose: Pain is a dominant symptom of psoriatic arthritis (PsA), and pain reduction is a priority for patients (pts) that is often assessed in clinical…
  • Abstract Number: 1441 • ACR Convergence 2020

    Effects of Belimumab on Renal Outcomes, Overall SLE Control and Biomarkers: Findings from a Phase 3, Randomized, Placebo-controlled 104-week Study in Patients with Active Lupus Nephritis

    Richard Furie1, Brad Rovin2, Frédéric Houssiau3, Gabriel Contreras4, Ana Malvar5, Amit Saxena6, Xueqing Yu7, Y K Onno Teng8, Pieter van Paassen9, Ellen M Ginzler10, Diane Kamen11, Mary Oldham12, Damon Bass13, Andre van Maurik14, Mary Beth Welch13, Yulia Green15, Beulah Ji15, Christi Kleoudis16 and David Roth17, 1Northwell Health, Great Neck, NY, 2The Ohio State University, Columbus, 3Cliniques Universitaires Saint-Luc, Brussels, Belgium, 4University of Miami Miller School of Medicine, Miami, 5Organizacion Medica de Investigacion, Buenos Aires, Argentina, 6NYU School of Medicine, New York, 7Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China (People's Republic), 8Leiden University Medical Center, Leiden, Netherlands, 9Maastricht University, Academisch Ziekenhuis Maastricht, Maastricht, Netherlands, 10SUNY Downstate Health Sciences University, Brooklyn, 11Medical University of South Carolina, Charleston, SC, 12GlaxoSmithKline, Stevenage, United Kingdom, 13GlaxoSmithKline, Research Triangle Park, 14GlaxoSmithKline, Stevenage, 15GlaxoSmithKline, Uxbridge, 16Parexel (*At the time of study), Durham, 17GlaxoSmithKline, Collegeville

    Background/Purpose: Belimumab (BEL) has demonstrated efficacy in systemic lupus erythematosus (SLE) in 4 positive pivotal trials. This study assessed the efficacy and safety of intravenous…
  • Abstract Number: 0897 • ACR Convergence 2020

    Temporal Achievement of Clinical Response and Inactive Disease Status in Patients with Axial Spondyloarthritis Treated with Etanercept

    Xenofon Baraliakos1, Annette Szumski2, Kenneth Kwok3 and Bonnie Vlahos4, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, 2Syneos Health, Princeton, 3Pfizer, New York, NY, 4Pfizer, Collegeville, PA

    Background/Purpose: Treatment with etanercept (ETN) is effective and well tolerated in patients with axial spondyloarthritis (AS), but the time frames within which patients tend to…
  • Abstract Number: 1444 • ACR Convergence 2020

    Cluster-randomized Pragmatic Clinical Trial Evaluating the Potential Benefit of a Tight-control and Treat-to-target Strategy in Axial Spondyloarthritis: The Results of the TICOSPA Trial

    Anna Molto1, Clementina Lopez-Medina2, Filip Van den Bosch3, Annelies Boonen4, Casper Webers4, Emmanuelle Dernis5, Floris van Gaalen6, Martin Soubrier7, Pascal Claudepierre8, Athan Baillet9, Mirian Starsman-Kool10, Anneke Spoorenberg11, Désirée van der Heijde12 and Maxime Dougados13, 1Rheumatology Department, Cochin Hospital, APHP, Paris, France, Paris, France, 2INSERM U1153, Universtity of Paris, PAris, France, 3Ghent University Hospital, Ghent, Belgium, 4Maastricht University Medical Center, Maastricht, Netherlands, 5CH Le Mans, department of rheumatology, Le Mans, France, 6Leiden University Medical Center (LUMC), Leiden, Netherlands, 7CHU Gabriel Montpied, Clermont-Ferrand, France, 8Hôpital Henri Mondor, Université Paris Est Créteil, EA 7379 EpiDermE, department of rheumatology, Créteil, France, 9CHU Grenoble, Echirolles, France, 10ATRIUM Medical Center, Heerlen, 11University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands, 12Leiden University Medical Center, Leiden, Netherlands, 13Université de Paris, Department of Rheumatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France

    Background/Purpose: Recommendations for axial spondyloarthritis (axSpA) management include tight control and treat-to-target (TC), but no study has evaluated its potential benefit. The objective of this…
  • Abstract Number: 0907 • ACR Convergence 2020

    Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA)

    Laura Coates1, Dafna Gladman2, Filip Van den Bosch3, Philip Helliwell4, Anna Rychlewska-Hańczewska5, Mykola Stanislavchuk6, Leen Gilles7, Lien Gheyle7, Ke Liu8, Mona Trivedi8, Muhsen Alani9, Robin Besuyen10 and Philip Mease11, 1University of Oxford, Oxford, United Kingdom, 2Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3Ghent University Hospital, Ghent, Belgium, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 5Ai Centrum Medyczne, Poznań, Poland, 6National Pirogov Memorial Medical University, Vinnytsya, Ukraine, 7Galapagos NV, Mechelen, Belgium, 8Gilead Sciences, Inc., Foster City, CA, 9Gilead Sciences, Inc. and University of Washington, Foster City, CA, 10Galapagos BV, Leiden, Netherlands, 11Seattle Rheumatology Associates, P.L.L.C., Seattle, WA

    Background/Purpose: EQUATOR (NCT03101670) was a randomized, 16-week, Phase 2, multicenter, double-blind, placebo (PBO)‑controlled trial of filgotinib (FIL) in patients with active PsA ( Mease P,…
  • Abstract Number: 1467 • ACR Convergence 2020

    Effectiveness of the Making It Work™ Program at Improving Presenteeism and Work Cessation in Workers with Inflammatory Arthritis – Results of a Randomized Controlled Trial

    Andre Luquini1, Yufei Zheng2, Hui Xie3, Catherine Backman1, Pamela Rogers3, Alex Kwok3, Astrid Knight3, Monique Gignac4, Dianne Mosher5, Linda Li1, John Esdaile6, Carter Thorne7 and Diane Lacaille1, 1University of British Columbia / Arthritis Research Canada, Richmond, BC, Canada, 2Simon Fraser University / Arthritis Research Canada, Richmond, BC, Canada, 3Arthritis Research Canada, Richmond, BC, Canada, 4Institute for Work & Health / University of Toronto, Toronto, ON, Canada, 5University of Calgary, Calgary, AB, Canada, 6Arthritis Research Canada, Vancouver, BC, Canada, 7Southlake Regional Health Centre, Newmarket, ON, Canada

    Background/Purpose: Arthritis often leads to presenteeism (decreased at-work productivity) and permanent work disability, the worst occupational outcome of a disease, leading to reduced quality of…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology